Elenco Poster Discussion Selezionate ID N. PGM Presenting Author Titolo 26/05/2014 11.45 - 12.45 Antiretroviral Therapy: alternative outcomes 4 PD 1 Substitution of nevirapine or raltegravir for protease inhibitor versus rosuvastatin treatment for the management of dyslipidemia in HIV-infected patients on stable antiretroviral therapy (NEVRAST Study). Preliminary results Leonardo Calza, Bologna 216 PD 2 Changes in routine laboratory tests after switching to co-formulated Rilpivirine-containing antiretroviral regimen: data from multicenter study group Massimiliano Fabbiani, Rome 334 PD 3 T-cell Phenotype and Function following DRV/r-based First cART in HIV+ Patients with Low CD4 Counts Camilla Tincati, Milano 40 PD 4 Monotherapy versus Combined Therapy Against Human Immunodeficiency Virus (HIV)-1: Impact on HIV-1 Reservoir, Immune Activation and Dynamics of Epstein-Barr Virus Coinfection Maria Raffaella Petrara, Padova 96 PD 5 Evolution of Cognitive Performance After Simplification to Dual Therapies in HIV+ Patients Nicoletta Ciccarelli, Rome 259 PD 6 Dynamics of cerebrospinal fluid (CSF) HIV decay and peculiar frequency/spatial features of EEG-LORETA in ART responder patients with CNS compartmentalized virus Magdalena Viscione, Rome 332 PD 7 Comparative features of HIV and HCV coinfected migrants vs nationals in the MaSTER cohort Paola Nasta, Brescia 303 PD 8 Cost assessment of HAART: the Ianua clinical trial in Genoa Antonio Di Biagio, Genova 26/05/2014 11.45 - 12.45 Comorbidities and coinfections 55 PD 9 Effects of antiretroviral molecules on survival and gene expression of bone markers in an osteoblast-like cell line Anna Miserocchi, Bologna 211 PD 10 Bone damage follow-up using calcaneal quantitative ultrasonography (QUS) in HIV-infected and -uninfected subjects Raffaella Marocco, Latina 179 PD 11 Prevalence and distribution of abdominal aortic calcification (AAC) and its relationship with vertebral fractures in HIV positive patients Nathalie Iannotti, Milano 77 PD 12 Concordance Among Cardiovascular Risk Scores in HIV-positive Patients: Framingham, D:A: D and Progetto Cuore Andrea Calcagno, Torino 287 PD 13 Survival after cardiovascular events in HIV-infected patients. Analysis data from a Brescia cohort Nigritella Brianese, Brescia 116 PD 14 Human papillomavirus anal infection and anal cytology among HIV-infected and HIVuninfected men who have sex with men Maria Gabriella Donà, Rome 149 PD 15 High frequencies of TNF-α-expressing Invariant Natural Killer T (iNKT) cells feature HIV-HBV co-infected patients Matteo Basilissi, Milan 182 PD 16 Host innate immune response to HIV and HCV infection: study of dendritic cell compartment Savinelli Stefano, Rome 27/05/2014 14.15 - 15.15 Antiretroviral therapy: clinical studies and pharmacology 315 PD 17 96-week efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF – subgroup analyses by baseline CD4 cells Antonella Castagna, Milano 288 PD 18 Virological outcomes of first line antiretroviral therapy in routine clinical practice Manuela Colafigli, Rome 324 PD 19 Dual therapy with Raltegravir associated to different Protease Inhibitors in HIV+ experienced patients: data of long-term longitudinal follow-up of 192 weeks Salvatore Martini, Napoli 230 PD 20 Once daily-one pill regimen is correlated to a better adherence 5-years later Ilaria Mastrorosa, Roma 10 PD 21 Efavirenz dose reduction in HIV-infected patients: a long-term follow-up Massimiliano Lanzafame, Verona Agg.al 09/05/14 Elenco Poster Discussion Selezionate Presenting Author ID N. PGM 245 PD 22 Intracellular Pharmacokinetics of Rilpivirine in HIV-positive Patients Treated with Singletablet Regimen Fixed-dose Combination Letizia Marinaro, Torino 273 PD 23 Drug concentrations of maraviroc, darunavir and ritonavir as a dual therapy switch in virologically suppressed patients with R5 virus: results from a multicenter randomized study (GUSTA) Roberta Gagliardini, Rome 86 PD 24 Relationship between the early Boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy. Chiara Simona Cardellino, Torino Titolo 27/05/2014 14.15 - 15.15 Basic and Clinical virology 319 PD 25 Decreasing trends of drug resistance and increase of non-B subtypes amongst subjects recently diagnosed as HIV infected over the period 2004-2014 Saverio Giuseppe Parisi, Padova 220 PD 26 Transmitted drug resistance and genetic diversity in Treatment-Naïve HIV-Infected Patients (2008-2013) Carmen Rita Santoro, Bari 236 PD 27 Drug resistance transmission clusters in HIV-1 infected patients in central Italy between 1997-2014 Lavinia Fabeni, Roma 295 PD 28 Impact of the HIV-1 subtype associated polymorphism L89M on virological response in patients starting their first boosted protease-inhibitor containing regimen Daniele Armenia, Roma 212 PD 29 Analysis of gp41 variability in subjects naïve for antiretrovirals Marco Franzetti, Milan 99 PD 30 Early clinical response and presence of viral resistant minority variants Generation GS Junior System 257 PD 31 HIV-1 genotyping in low and very low viral load Bianca Bruzzone, Genova 188 PD 32 Comparison between pseudoviruses ands T/F IMCs in the synergy of antibody neutralization Assunta Venuti, Milan Agg.al 09/05/14 detected by Next Annapaola Callegaro, Bergamo